SAGE Therapeutics (NASDAQ:SAGE) had its price target lowered by Morgan Stanley from $217.00 to $125.00 in a research report sent to investors on Friday, BenzingaRatingsTable reports. Morgan Stanley currently has an overweight rating on the biopharmaceutical company’s stock.
A number of other equities research analysts have also recently commented on the stock. Piper Jaffray Companies lowered their price objective on shares of SAGE Therapeutics from $206.00 to $125.00 and set an overweight rating on the stock in a research note on Thursday. Goldman Sachs Group cut their target price on shares of SAGE Therapeutics from $227.00 to $263.00 in a research report on Thursday. Svb Leerink raised shares of SAGE Therapeutics from an underperform rating to a market perform rating in a report on Friday. Stifel Nicolaus reiterated a buy rating on shares of SAGE Therapeutics in a research report on Wednesday, November 20th. Finally, SunTrust Banks lowered shares of SAGE Therapeutics from a buy rating to a hold rating and lowered their price target for the company from $210.00 to $70.00 in a research report on Thursday. One investment analyst has rated the stock with a sell rating, six have given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of Buy and an average target price of $128.81.
SAGE stock opened at $64.46 on Friday. The firm has a 50 day moving average of $142.30 and a 200-day moving average of $160.81. The company has a market cap of $3.34 billion, a price-to-earnings ratio of -7.98 and a beta of 2.52. The company has a current ratio of 12.67, a quick ratio of 12.67 and a debt-to-equity ratio of 0.03. SAGE Therapeutics has a 12-month low of $56.50 and a 12-month high of $193.56.
SAGE Therapeutics (NASDAQ:SAGE) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($3.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.41) by ($0.07). The firm had revenue of $3.57 million during the quarter, compared to analyst estimates of $2.52 million. SAGE Therapeutics had a negative net margin of 12,931.34% and a negative return on equity of 60.00%. The firm’s revenue for the quarter was up 35600.0% on a year-over-year basis. During the same period last year, the company posted ($2.63) EPS. Sell-side analysts forecast that SAGE Therapeutics will post -13.77 earnings per share for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in the business. Point72 Hong Kong Ltd acquired a new position in SAGE Therapeutics in the 2nd quarter valued at $44,000. Wealthcare Advisory Partners LLC lifted its stake in shares of SAGE Therapeutics by 150.0% during the 3rd quarter. Wealthcare Advisory Partners LLC now owns 250 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 150 shares during the period. Tobam acquired a new stake in shares of SAGE Therapeutics during the second quarter worth $92,000. Tower Research Capital LLC TRC acquired a new stake in shares of SAGE Therapeutics during the second quarter worth $111,000. Finally, Athanor Capital LP acquired a new stake in shares of SAGE Therapeutics during the second quarter worth $201,000.
About SAGE Therapeutics
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).
Featured Article: Return on Investment (ROI) Defined, Explained
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.